Australia’s Garvan Institute of Medical Research has shown in preclinical models that palbociclib effectively targets a major subtype of pancreatic cancer that affects two-thirds of all patients with the deadly disease.
Patient trials are underway and lead research author Dr Marina Pajic says it’s hoped the drug can be easily repurposed. Read more . . .